Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;56(7):1651-1664.
doi: 10.1038/s41409-021-01227-8. Epub 2021 Feb 23.

Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

Jakob R Passweg  1 , Helen Baldomero  2 , Christian Chabannon  3 , Grzegorz W Basak  4 , Rafael de la Cámara  5 , Selim Corbacioglu  6 , Harry Dolstra  7 , Rafael Duarte  8 , Bertram Glass  9 , Raffaella Greco  10 , Arjan C Lankester  11 , Mohamad Mohty  12 , Régis Peffault de Latour  13 , John A Snowden  14 , Ibrahim Yakoub-Agha  15 , Nicolaus Kröger  16 ; European Society for Blood and Marrow Transplantation (EBMT)
Affiliations

Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

Jakob R Passweg et al. Bone Marrow Transplant. 2021 Jul.

Abstract

Numbers of Hematopoietic cell transplantation (HCT) in Europe and collaborating countries continues to rise with 48,512 HCT in 43,581 patients, comprising of 19,798 (41%) allogeneic and 28,714 (59%) autologous, reported by 700 centers in 51 countries during 2019. Main indications were myeloid malignancies 10,764 (25%), lymphoid malignancies 27,895 (64%), and nonmalignant disorders 3173 (7%). A marked growth in CAR-T cellular therapies from 151 in 2017 to 1134 patients in 2019 is observed. This year's analyses focus on changes over 30 years. Since the first survey in 1990 where 143 centers reported 4234 HCT, the number has increased to 700 centers and 48,512 HCT. Transplants were reported in 20 countries in 1990, and 51, 30 years later. More than 800,000 HCT in 715,000 patients were reported overall. Next to the massive expansion of HCT technology, most notable developments include the success of unrelated donor and haploidentical HCT, an increase followed by decrease in the number of cord blood transplants, use of reduced intensity HCT in older patients, and the phenomenal rise in cellular therapy. This annual report of the European Society for Blood and Marrow Transplantation (EBMT) reflects current activity and highlights important trends vital for health care planning.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests. The writing of the paper was the sole responsibility of the authors.

Figures

Fig. 1
Fig. 1. Relative proportion of disease indications for HCT in Europe 2019.
a Relative proportion of allogeneic HCT. b Relative proportion of autologous HCT.
Fig. 2
Fig. 2
Continued.
Fig. 2
Fig. 2
Continued.
Fig. 3
Fig. 3. Development of HCT from 1990 to 2019.
a Number of patients receiving autologous and allogeneic HCT. b Distribution of donor type among allogeneic HCT recipients.
Fig. 4
Fig. 4. Change in choice of stem cell source for allogeneic HCT from 1990 to 2019.
Figure shows the change in the use of bone marrow (BM), peripheral blood (PB) and cord blood (CB) as stem cell source over the 30 year period.
Fig. 5
Fig. 5. Change in choice of donor type by center from 1990 to 2019.
The figure shows the numbers of centers and the type of donors selected for HCT over the 30 year period.
Fig. 6
Fig. 6. Change in HCT for lymphomas 1990–2019.
a Autologous HCT for Hodgkin and non-Hodgkin lymphoma. b Allogeneic HCT for Hodgkin and non-Hodgkin lymphoma.
See this image and copyright information in PMC

References

    1. Gratwohl A. Bone marrow transplantation activity in Europe 1990. Report from the European Group for Bone Marrow Transplantation (EBMT) Bone Marrow Transplant. 1991;8:197–201. - PubMed
    1. Copelan EA, Chojecki A, Lazarus HM, Avalos BR. Allogeneic hematopoietic cell transplantation; the current renaissance. Blood Rev. 2019;34:34–44. doi: 10.1016/j.blre.2018.11.001. - DOI - PubMed
    1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357:1472–5. doi: 10.1056/NEJMp078166. - DOI - PubMed
    1. Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019;54:1525–52. doi: 10.1038/s41409-019-0516-2. - DOI - PubMed
    1. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617–24. doi: 10.1001/jama.2010.491. - DOI - PMC - PubMed

Publication types